Bioavailability of EPA + DHA in a SMEDS Formulation
Status:
Completed
Trial end date:
2018-04-15
Target enrollment:
Participant gender:
Summary
This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) +
docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation
compared with a standard omega-3-acid ethyl ester product in healthy men and women.
Phase:
Phase 4
Details
Lead Sponsor:
Midwest Center for Metabolic and Cardiovascular Research